Details of the Drug

General Information of Drug (ID: DM7ICNU)

Drug Name

Doxycycline

Synonyms

Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline

Indication

Disease Entry	ICD 11	Status	REF
Advanced gum disease	DA0D	Approved	[1], [2]
Chronic periodontitis	DA0C.Y	Approved	[1], [2]
Diabetic foot ulcer	BD54	Phase 2	[3]

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

444.4

Topological Polar Surface Area (xlogp)

-0.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability: 93% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The clearance of drug is 75 mL/min [6]
Elimination: Between 40% and 60% of an administered dose can be accounted for in the urine by 92 hours, and approximately 30% can be accounted for in the feces [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 16.33 +/- 4.53 hours [7]
Metabolism: The drug is metabolized via the liver [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.4285 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.12% [9]
Vd: The volume of distribution (Vd) of drug is 0.7 L/kg [6]

Chemical Identifiers

Formula: C22H24N2O8
IUPAC Name: (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
Canonical SMILES: C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
InChI: InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
InChIKey: SGKRLCUYIXIAHR-AKNGSSGZSA-N

Cross-matching ID

PubChem CID: 54671203
ChEBI ID: CHEBI:50845
CAS Number: 564-25-0
DrugBank ID: DB00254
TTD ID: D0S0LZ
VARIDT ID: DR00666
INTEDE ID: DR0547
ACDINA ID: D00215

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial 30S ribosomal RNA (Bact 30S rRNA)	TTOVFH2	NOUNIPROTAC	Modulator	[10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Doxycycline (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Doxycycline and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[36]
Sodium bicarbonate	DMMU6BJ	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Doxycycline caused by Sodium bicarbonate mediated altered urine pH.	Acidosis [5C73]	[37]
Tromethamine	DMOBLGK	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Doxycycline caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[37]
Tretinoin	DM49DUI	Major	Increased risk of pseudotumor cerebri by the combination of Doxycycline and Tretinoin.	Acne vulgaris [ED80]	[38]
Isotretinoin	DM4QTBN	Major	Increased risk of pseudotumor cerebri by the combination of Doxycycline and Isotretinoin.	Acne vulgaris [ED80]	[38]
Sucralfate	DMP9HBO	Moderate	Decreased absorption of Doxycycline due to formation of complexes caused by Sucralfate.	Acne vulgaris [ED80]	[39]
Magnesium Sulfate	DMVEK07	Moderate	Decreased absorption of Doxycycline due to formation of complexes caused by Magnesium Sulfate.	Acute pain [MG31]	[40]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Doxycycline and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[41]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Doxycycline caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[42]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Doxycycline caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[43]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Doxycycline and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[44]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Doxycycline caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[42]
Mestranol	DMG3F94	Moderate	Decreased absorption of Doxycycline due to formation of complexes caused by Mestranol.	Contraceptive management [QA21]	[45]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Doxycycline and Mivacurium.	Corneal disease [9A76-9A78]	[46]
Methohexital	DM7YMIT	Moderate	Increased metabolism of Doxycycline caused by Methohexital mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[42]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Doxycycline and Pancuronium.	Corneal disease [9A76-9A78]	[46]
Thiopental	DMGP8AX	Moderate	Increased metabolism of Doxycycline caused by Thiopental mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[42]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Doxycycline caused by Oxtriphylline mediated inhibition of CYP450 enzyme.	Cough [MD12]	[43]
Mycophenolic acid	DMU65NK	Moderate	Altered absorption of Doxycycline due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[47]
PMID28870136-Compound-48	DMPIM9L	Moderate	Decreased metabolism of Doxycycline caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[43]
Primidone	DM0WX6I	Moderate	Increased metabolism of Doxycycline caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Mephenytoin	DM5UGDK	Moderate	Increased metabolism of Doxycycline caused by Mephenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Doxycycline caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Doxycycline caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Doxycycline caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Digoxin	DMQCTIH	Moderate	Altered absorption of Doxycycline due to GI flora changes caused by Digoxin.	Heart failure [BD10-BD1Z]	[49]
Digitoxin	DMWVIGP	Moderate	Altered absorption of Doxycycline due to GI flora changes caused by Digitoxin.	Heart failure [BD10-BD1Z]	[49]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Doxycycline caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[50]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Doxycycline and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[51]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Doxycycline and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[52]
Quinapril	DMR8H31	Moderate	Decreased absorption of Doxycycline due to formation of complexes caused by Quinapril.	Hypertension [BA00-BA04]	[53]
Sodium acetate anhydrous	DMH21E0	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Doxycycline caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[37]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Doxycycline caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[42]
Pentobarbital	DMFNH7L	Moderate	Increased metabolism of Doxycycline caused by Pentobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[42]
Iron	DMAP8MV	Moderate	Decreased absorption of Doxycycline due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[54]
Methotrexate	DM2TEOL	Moderate	Increased plasma concentration of Doxycycline and Methotrexate due to competitive binding of plasma proteins.	Leukaemia [2A60-2B33]	[55]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Doxycycline and Porfimer Sodium.	Lung cancer [2C25]	[56]
Quinine	DMSWYF5	Minor	Decreased metabolism of Doxycycline caused by Quinine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[57]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Doxycycline and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[58]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Doxycycline and Idelalisib.	Mature B-cell leukaemia [2A82]	[59]
Ethinyl estradiol	DMODJ40	Moderate	Decreased absorption of Doxycycline due to formation of complexes caused by Ethinyl estradiol.	Menopausal disorder [GA30]	[45]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Doxycycline due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[55]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Doxycycline caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[50]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Doxycycline and Methoxsalen.	Mycosis fungoides [2B01]	[36]
Ranitidine	DM0GUSX	Moderate	Decreased absorption of Doxycycline due to formation of complexes caused by Ranitidine.	Peptic ulcer [DA61]	[60]
Acitretin	DM8BKU9	Major	Increased risk of pseudotumor cerebri by the combination of Doxycycline and Acitretin.	Psoriasis [EA90]	[38]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Doxycycline and Verteporfin.	Psoriasis [EA90]	[53]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Doxycycline and Vecuronium.	Tonus and reflex abnormality [MB47]	[46]
Cisatracurium	DMUZPJ5	Moderate	Additive neuromuscular blocking effects by the combination of Doxycycline and Cisatracurium.	Tonus and reflex abnormality [MB47]	[46]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Doxycycline and Rocuronium.	Tonus and reflex abnormality [MB47]	[46]
Mycophenolate mofetil	DMPQAGE	Moderate	Altered absorption of Doxycycline due to GI flora changes caused by Mycophenolate mofetil.	Transplant rejection [NE84]	[47]
-----------


⏷ Show the Full List of 51 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acetic acid	E00002	176	Acidulant; Buffering agent
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
Docusate sodium	E00563	23673837	Surfactant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol monostearate	E00239	14878	Emollient; Emulsifying agent; Surfactant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 42 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Doxycycline 100 mg capsule	100 mg	Oral Capsule	Oral
Doxycycline 50 mg capsule	50 mg	Oral Capsule	Oral
Doxycycline 75 mg capsule	75 mg	Oral Capsule	Oral
Doxycycline 20 mg tablet	20 mg	Oral Tablet	Oral
Doxycycline 150 mg capsule	150 mg	Oral Capsule	Oral
Doxycycline 200 mg tablet	200 mg	Delayed Release Oral Tablet	Oral
Doxycycline 50 mg tablet	50 mg	Delayed Release Oral Tablet	Oral
Doxycycline 100 mg tablet	100 mg	Delayed Release Oral Tablet	Oral
Doxycycline 120 mg tablet	120 mg	Delayed Release Oral Tablet	Oral
Doxycycline 150 mg tablet	150 mg	Delayed Release Oral Tablet	Oral
Doxycycline 60 mg tablet	60 mg	Delayed Release Oral Tablet	Oral
Doxycycline 75 mg tablet	75 mg	Delayed Release Oral Tablet	Oral
Doxycycline 100 mg tablet	100 mg	Oral Tablet	Oral
Doxycycline 150 mg tablet	150 mg	Oral Tablet	Oral
Doxycycline 50 mg tablet	50 mg	Oral Tablet	Oral
Doxycycline 75 mg tablet	75 mg	Oral Tablet	Oral
Doxycycline 40 mg capsule	40 mg	Delayed Release Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6464).
2	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
3	ClinicalTrials.gov (NCT00764361) Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers. U.S. National Institutes of Health.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
12	A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):272-8.
13	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
23	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
24	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
25	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
26	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
27	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
28	The antibiotic Furvina targets the P-site of 30S ribosomal subunits and inhibits translation initiation displaying start codon bias. Nucleic Acids Res. 2012 Nov 1;40(20):10366-74.
29	Mechanism of action of aminoglycoside antibiotics.Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits.Eur J Biochem.1979 Dec;102(1):73-81.
30	The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.Expert Opin Pharmacother. 2018 Oct 22:1-13.
31	Omadacycline Enters the Ring: A New Antimicrobial Contender.Pharmacotherapy. 2018 Dec;38(12):1194-1204.
32	Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18.
33	ClinicalTrials.gov (NCT01961830) Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers. U.S. National Institutes of Health.
34	Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals.
35	Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals.
36	Cerner Multum, Inc. "Australian Product Information.".
37	Elliott GR "Sodium bicarbonate and oral tetracycline." Clin Pharmacol Ther 13 (1972): 459. [PMID: 5026384]
38	Gardner K, Cox T, Digre KB "Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review." Neurology 45 (1995): 6-10. [PMID: 7824136]
39	Cerner Multum, Inc. "Canadian Product Information.".
40	Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
41	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
42	Neuvonen PJ, Penttila O "Interaction between doxycycline and barbiturates." Br Med J 1 (1974): 535-6. [PMID: 4817187]
43	Gotz VP, Ryerson GG "Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease." Drug Intell Clin Pharm 20 (1986): 694-6. [PMID: 3757782]
44	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
45	Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
46	Multum Information Services, Inc. Expert Review Panel.
47	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
48	Neuvonen PJ, Penttila O, Lehtovaara R, Aho K "Effect of antiepileptic drugs on the elimination of various tetracycline derivatives." Eur J Clin Pharmacol 9 (1975): 147-54. [PMID: 1233262]
49	Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR "Inactivation of digoxin by the gut flora: reversal by antibiotic therapy." N Engl J Med 305 (1981): 789-94. [PMID: 7266632]
50	Colmenero JD, Fernandezgallardo LC, Agundez JAG, Sedeno J, Benitez J, Valverde E "Possible implications of doxycycline-rifampin interaction for treatment of brucellosis." Antimicrob Agents Chemother 38 (1994): 2798-802. [PMID: 7695265]
51	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
52	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
53	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
54	Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5. [PMID: 2054263]
55	Canadian Pharmacists Association.
56	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
57	Zhao XJ, Ishizaki T "A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (K-i) and type of inhibition." Eur J Drug Metab Pharm 24 (1999): 272-8. [PMID: 10716067]
58	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
59	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
60	Albert KS, Welch RD, DeSante KA, DiSanto AR "Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture." J Pharm Sci 68 (1979): 586-8. [PMID: 435335]